GH Research PLC (GHRS)

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year PR...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

GH Research Announces Publication of Phase 2a Postpartum Depression Results

DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS) today announced the publication of...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form EFFECT - Notice of Effectiveness

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form F-3 - Registration statement by foreign private issuers

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

Phase 2b results in TRD published in JAMA PsychiatryGH001-HV-106 study enrolment completed; doses selected for...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]